All lobbying filings

The Nickles Group, LLC

The Nickles Group, LLC filed a Q2 report for Emergent Biosolutions on July 15, 2026, reporting $40,000 in lobbying income.

Lobbying for Emergent Biosolutions · Pharmaceutical company.

As filed: THE NICKLES GROUP, LLC for EMERGENT BIOSOLUTIONS.

All filings by The Nickles Group, LLC · Everything Emergent Biosolutions has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 15, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 3

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Budget/Appropriations

Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield. Opioid and heroin addiction legislation, naloxone access and awareness.

Health Issues

Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, H.R. 8800 / S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.

Defense

S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.

Bills named in this filing 2

H.R. 8800
National Defense Authorization Act for Fiscal Year 2027
S. 4784
National Defense Authorization Act for Fiscal Year 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.